Who
Linda Bain
Director
Company insider
Files Form 4 as: Director, Autolus Therapeutics; Director, Arvinas; Chief Financial Officer, Codiak BioSciences; Director, VBI Vaccines Inc/BC; Chief Financial Officer, Avalanche Biotechnologies; VP, Fin. & Business Operations, bluebird bio.
In numbers
- Trades disclosed
- 75
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $644K
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 16 Dec 2013
- Last trade
- 29 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,500 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,500 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —15,527 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,714 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,714 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —15,527 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,105 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —16,025 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,070 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —5,899 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,787 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —4,121 at $0.00 | filing |
| 28 Mar 2023filed 30 Mar 2023 | Codiak BioSciences | SEC FORM 4 Sold | $2,28013,412 at $0.17 | filing |
| 17 Feb 2023filed 21 Feb 2023 | Codiak BioSciences | SEC FORM 4 Sold | $1,5162,570 at $0.59 | filing |
| 16 Feb 2023filed 21 Feb 2023 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code M | —7,613 at $0.00 | filing |
| 16 Feb 2023filed 21 Feb 2023 | Codiak BioSciences | SEC FORM 4 Code M | —7,613 | filing |
| 24 Jan 2023filed 26 Jan 2023 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 20 Jan 2023filed 23 Jan 2023 | Codiak BioSciences | SEC FORM 4 Sold | $1,0901,880 at $0.58 | filing |
News
No headline names them, or the companies they trade most, lately.